TRU-016 is an intravenously administered anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies, including CLL and non-Hodgkin's lymphoma (NHL).27,28 TRU-016 was created by humanizing SMIP-016, a mouse/human chimeric protein with preclinical antitumor activity against lymphoid malignancies. This evidence concerns the gene CD37 and non-Hodgkin lymphoma.